Gastric Cancer RAD001 Study

• Status: Completed
• Trial end date: 2019-03-06

Summary

The purpose of this study is to determine dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of RAD001, as well as to assess tumor response and overall survival.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Chinese University of Hong Kong
• Treatments: Carboplatin; Everolimus; Paclitaxel; Sirolimus